# A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

> **NCT06863272** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 360 (estimated)

## Conditions studied

- Castration-Resistant Prostatic Cancer
- Metastasis

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Ifinatamab Deruxtecan
- **DRUG:** MK-5684
- **DRUG:** Abiraterone
- **DRUG:** Enzalutamide
- **DRUG:** Rescue Medication

## Key facts

- **NCT ID:** NCT06863272
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-03
- **Primary completion:** 2031-04-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863272, "A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06863272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*